




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/12, 5/10, 1/21, C07K 14/71, 16/28, G01N 33/50, A61K 38/17		A1	(11) International Publication Number: <b>WO 99/66038</b>
			(43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/EP99/04109		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 June 1999 (11.06.99)		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 9802130-6 15 June 1998 (15.06.98) SE 60/089,266 15 June 1998 (15.06.98) US 9804372-2 17 December 1998 (17.12.98) SE 60/114,386 29 December 1998 (29.12.98) US			
(71) Applicant (for all designated States except US): PHARMACIA & UPIOHN AB [SE/SE]; S-112 87 Stockholm (SE).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): HOLMGREN, Lars [SE/SE]; Snackvagen 14, S-167 53 Bromma (SE). TROYANOVSKY, Boris [UA/SE]; Apartment 202, Rinkebysvangen 91 - Lagenhet 202, S-163 74 Spanga (SE).			
(74) Agent: MAZZINI, Giuseppe; Pharmacia & Upjohn S.p.A., Viale Pasteur, 10, I-20014 Nerviano (IT).			

(54) Title: ANGIOSTATIN-BINDING PROTEIN



## (57) Abstract

The present invention provides the sequence of a protein capable of acting as an angiostatin receptor as well as the nucleic acid sequence thereof. The invention also relates to the use thereof in screening methods, wherein novel substances are created exhibiting the same advantageous anti-angiogenic properties as angiostatin.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ANGIOSTATIN-BINDING PROTEIN

Technical field

5       The present invention relates to the field of angiogenesis, and more specifically to novel molecules, such as proteins and peptides, whereby novel anti-angiogenic substances may be developed. The invention also relates to methods for developing such substances.

Background

10       Almost all of the tissue of a mammalian body comprises a fine mesh of very thin blood vessels, each of which is thinner than a human hair. Usually, neither the number nor the size of these vessels increase, since the division of the endothelial cells covering the vessels is slow, actually up to several years. The exceptions are for example during wound healing and menstruation, when the vessels grow rapidly. However, that is during a limited period of time and the cell division ceases thereafter.

15       The generation of new blood vessels from existing ones is called angiogenesis. Angiogenesis has been associated to cancer and the formation of tumors as well as to other conditions, such as diabetes retinopathy, rheumatoid arthritis and even some inflammatory conditions. Accordingly, a considerable research effort is made world-wide to find ways of preventing and inhibiting the angiogenic process. If this were possible, tumor growth could  
20       be controlled and useful therapies could be developed regarding the above mentioned conditions.

25       There exists numerous pieces of evidence showing that tumors are depending on *de novo* formation of blood vessels for expansion beyond a mass of a few mm<sup>3</sup>. The angiogenesis is triggered by factors secreted by the tumor cells. It has recently been discovered that tumors through unleashed proteolytic activity generates peptide fragments, which show anti-angiogenic activities. One example is the molecule angiostatin, which is a fragment of plasminogen.

30       Plasminogen is a substance in blood plasma which, when activated, forms plasmin or fibrinolysin, an enzyme involved in the coagulation of blood. Plasminogen itself lacks any detectable anti-angiogenic activity. It has been found (Judah Folkman et al, Harvard Medical School, Boston) that a part of this endogenous protein, more specifically the first four kringle domains, is capable of preventing the endothelial cells from dividing. This part

of plasminogen has been denoted angiostatin, and a great deal of research within this field is centred around this molecule. The prior art has shows that angiostatin inhibits endothelial cells specifically *in vitro* and blocks angiogenesis *in vivo*. Systemic treatments with subcutaneous injections of angiostatin induces *in vivo* dormancy in a wide range of tumors  
5 in SCID mice (O'Reilly et al., Nature Med., vol. 2, p. 689, 1996). No detectable toxicity has been detected in these animals even after months of treatment. Angiostatin shows two levels of specificity: it induces apoptosis specifically in endothelial cells *in vitro* (Claesson-Welsh et al., Proc. Natl. Acad. Sci., USA, vol. 95, p. 5579, 1998) and only affects endothelial cells active in angiogenesis *in vivo*. It has not shown to negatively affect cells in  
10 established vessels.

Angiostatin does indeed exhibit some advantageous properties, *inter alia* as it is an endogenous substance. However, the disadvantages associated with its possible use for medical purposes cannot be neglected. One is that the half life thereof is very short, it may be counted in hours, thereby requiring a frequent administration thereof. This far, the  
15 efficiency thereof has proven to be rather low, which fact necessitates the use of large doses thereof. These two disadvantages are in themselves strong motives for directing further research towards the finding of alternative, smaller and/or more efficient molecules to be used as medicaments.

## 20 Summary of the invention

The present invention solves the problems associated with angiostatin as defined above by providing a human protein, which has been named "ABP-1", defined by its ability to bind a fragment of plasminogen, preferably the first four Kringle domains (K1-K4) thereof, the said fragment being characterized by anti-angiogenic biological activity.

25 ABP-1 comprises an amino acid sequence substantially similar to that shown in SEQ ID NO. 2. Variants and fragments of ABP-1 are encompassed in the present invention.

Also encompassed in the present invention are the homologs of ABP-1 in other species, especially in other mammals.

In a further aspect, the invention provides isolated nucleic acid molecules comprising  
30 a sequence that codes for ABP-1 or for a polypeptide substantially similar to ABP-1, including its variants, fragments and homologs.

It is another object of the present invention to provide nucleic acid probes whose sequence is derived from SEQ ID NO. 1; these probes may be used as research tools as well as in diagnostic methods, for example to detect and measure ABP-1 biosynthesis in tissues and cells.

5 Accordingly, it is an object of the present invention to provide a diagnostic method for detecting the presence and the amount of ABP-1 or its variants and fragments in tissues and cells.

The present invention also includes screening methods for identifying a compound capable of interacting with ABP-1 or its variants and fragments. The screening method can  
10 be in any configuration well known to those skilled in the art.

It is a further object of the present invention to provide compounds identified with the said screening method and capable of modulating the biological activity of ABP-1 or its variants and fragments.

It is a further object of the present invention to provide a pharmaceutical composition  
15 comprising as active ingredient the compound identified with the above screening method.

It is still a further object of the present invention to provide antibodies directed against epitopes present in ABP-1 or its variants and fragments as well as cell producing the antibody.

It is a further object of the present invention to provide a vector comprising the  
20 nucleotide sequence of ABP-1 or its variants and fragments.

It is a further object of the present invention to provide a cell containing the above vector.

### Definitions

25 In the present application, the following terms are used in the meanings defined below.

As used herein, the term "angiogenesis" relates to the generation of new blood vessels into a tissue or organ. As mentioned above, under normal physiological conditions, humans and animals undergo angiogenesis only in very specific restricted situations. For example,  
30 angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum and placenta.

The term "endothelium" relates to the thin layer of flat epithelial cells, that lines serous cavities, lymph vessels and blood vessels. The term "endothelial inhibiting activity" relates to the capability of inhibiting the growth of endothelial capillary endothelial cells.

5 The term "an angiogenesis associated protein" relates to a protein capable of interacting in the angiogenesis, such as a receptor binding an anti-angiogenic substance.

The term "substantially similar", when used in reference to the amino acid sequence of SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4, means an amino acid sequence having an high degree of sequence homology to SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. A high degree of homology means at least approximately 80% amino acid homology, preferably at least approximately 90% amino acid homology, more preferably at least approximately 95% amino acid homology and most preferably at least approximately 98% amino acid homology.

15 The term "specifically hybridizing to" refers to the binding, duplexing or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when the sequence is present in a complex mixture (e.g. total cellular) of DNA or RNA. The term "stringent conditions" relates to conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than  
20 the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be  
25 those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g. 10 to 50 nucleotides) and at least about 60°C for longer probes. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Brief description of the drawings

Figure 1 shows the binding of  $^{125}$ I-labelled angiostatin and plasminogen to bovine microcapillary endothelial cells *in vitro*. Units in abscissa represent the fold molar excess of cold angiostatin and plasminogen, respectively.

5        Figure 2 shows the strategy for isolating angiostatin binding proteins.

Figure 3 shows the growth of positive yeast clones under selective conditions.

Figure 4 compares the binding of recombinant "Big-3" to angiostatin and plasminogen, respectively.

Figure 5 is a map over "Big-3".

10       Figure 6 shows the open reading frame (Frame 2) of the gene encoding the angiostatin receptor according to the invention. The other possible frames do not produce any putative protein.

Figure 7 shows the expression patterns of fetal and adult mRNA as well as endothelial cells.

15       Figure 8 shows the relative quantitation of ABP-1 gene expression in different tissue. See experimental section for more details.

Figure 9 illustrates (A) the cellular localization of GFP-tagged ABP-1 receptor in transiently transfected HeLa cells and (B) the reorganization of GFP-labeled ABP-1 after incubation with angiostatin. Figure 9C shows the binding of angiostatin to ABP-1. See the  
20       experimental section for more details. Figure 9D is an immunostaining of ABP-1 in Human umbilical cord endothelial (HUVE) cells together with staining against F-actin with rhodamin-labelled phalloidin. ABP-1 is localized in focal adhesions and membrane ruffles (arrows).

Figure 10 illustrates the down regulation of ABP-1 associated kinase activity after  
25       addition of angiostatin.

Figure 11 is an autoradiography of an SDS-PAGE demonstrating that ABP-1 mediates angiostatin-induced focal adhesion kinase activity. See experimental section for more details.

30       Detailed description of the invention

The present invention relates to an isolated human angiogenesis-associated protein capable of binding a fragment of plasminogen, preferably an N-terminal fragment, such as

kringle domains 1 to 4 and/or kringle 5. Thus, the protein of the invention acts as a receptor of plasminogen fragments, in particular as a receptor of angiostatin and/or kringle 5 domain of plasminogen. The protein of the invention can be synthesized by biological or chemical methods (e.g. recombinant gene expression and peptide synthesis). Recombinant techniques  
5 include gene cloning or amplification by *in vitro* methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS) or the self-sustained sequence replication system (SSR). A wide variety of cloning and *in vitro* amplification methodologies are well-known to those skilled in the art. Examples of these techniques are e.g. found in Berger and Kimmel, *Guide to Molecular*  
10 *Cloning Techniques*, Methods in Enzymology 152 Academic Press, Inc., San Diego, CA (Berger). The present invention includes proteins which comprise amino acid sequences substantially similar to those shown in SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. A comparison of the protein sequence of SEQ ID NO. 2 with the sequences present in all available data bases showed a homology of 23.7% with a hypothetical protein of  
15 *Caenorhabditis elegans* encoded by a putative open reading frame located in the central cluster of chromosome III of this organism (described in R. Wilson et al., Nature, vol.368, 3 March 1994, p. 32-38). No function has been attributed to this hypothetical protein.

According to the definition given above, it is to be understood that all polypeptides capable of binding a fragment of plasminogen and having an amino acid sequence which  
20 has at least approximately 80% sequence homology, preferably approximately 90% sequence homology, more preferably approximately 95% sequence homology and most preferably approximately 98% sequence homology to SEQ ID Nos.2, 3 or 4, are contemplated as being included in the present invention. These variant forms may result, e.g., from alternative splicing or differential expression in different tissue of the same  
25 source organism. The variant forms may be characterized by, e.g., amino acid insertion, deletion or substitution. A preferred variant form of ABP-1 is illustrated in SEQ ID NO. 3 (see below).

A particularly preferred embodiment of the present invention is a fragment of ABP-1 named Big-3 which will be described in greater details below and which includes the  
30 angiostatin-binding domain of ABP-1 (SEQ ID NO. 4).

In a further embodiment, the present invention provides peptides which comprises at least about 5, preferably at least about 10 contiguous amino acid residues of SEQ ID NO 2



or any variant or fragment thereof. However, the most advantageous size of the peptide will be depending on the intended future use thereof and the present invention is not limited to the above stated number of amino acids residues.

Also included in the present invention are homologs of ABP-1 and Big-3 in other species, in particular in other mammals. The term "homolog" refers to proteins exerting substantially the same biological function of the proteins of the invention, regardless of the homology existing between the corresponding amino acid sequences.

In another aspect, the present invention relates to isolated nucleic acid molecules comprising a sequence that codes for the proteins and peptides of the invention, including the variants, fragments and homologs as defined above. In a preferred embodiment, the nucleic acid molecule has the sequence of SEQ ID NO. 1. This sequence presents a 5' (from nucleotide 1 to nucleotide 796) and a 3' (from nucleotide 2825 to nucleotide 6463) untranslated regions. In another preferred embodiment the nucleic acid molecule has the sequence from nucleotide 797 to nucleotide 2824 of SEQ ID NO. 1. In another preferred embodiment the nucleic acid sequence encodes the ABP-1 fragment named Big-3 (illustrated in SEQ ID NO. 4) and it comprises the nucleotide sequence from position 2180 to position 2608 of SEQ ID NO. 1. All the nucleotide sequences encoding the polypeptides of the invention and differing from the nucleotide sequence of SEQ ID NO. 1 or fragment thereof by way of the degeneracy of the genetic code, are considered part of the invention. Sequencing analysis has revealed the presence of a possible polymorphism in the codon 1199-1201 of SEQ ID NO. 1, wherein a codon for Asn, Ser or Asp may be present; a further region corresponding to nucleotide positions 1238 to 1246 of SEQ ID NO.1 has been found to code for the tripeptide Glu-Leu-Ala or for the tripeptide Thr-Trp-Pro. These variations in the amino acid sequence of ABP-1 are illustrated in SEQ ID NO. 3 which constitutes another preferred protein of the invention. Also included in the present invention are nucleotide molecules encoding a homolog of ABP-1 or fragment thereof.

The present invention further comprises a nucleic acid capable of specifically hybridizing, under stringent conditions, to any one of the nucleic acid molecules of the invention described above.

Where the nucleic acids according to the invention are to be used as probes, it is often desirable to label the sequences with detectable markers. Such markers may include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical,

electrical, optical or chemical means. The markers may be incorporated by any of a number of means well known to those of skill in the art. Methods for detecting such markers are also well known in the art and disclosed in the literature. The probes find a useful application in diagnostic application, for example to detect and measure ABP-1  
5 biosynthesis in tissues and cells.

In another aspect, the present invention provide screening methods or assays, wherein molecules that exhibit the same properties as angiostatin and/or krigle 5 are screened for. In a typical screening method a compound capable of activating the angiostatin signal transduction pathway is identified through a high throughput cell-based screen. Such screen  
10 rely on a reporter gene driven by an angiostatin responsive element that is stably transfected into an angiostatin-responsive cell line. The responsive element is linked to a reporter gene, e.g. the gene for luciferase; upon binding of the compound to the protein of the invention, the intracellular pathway is activated thus causing an increase in the reporter gene activity that can be detected.

15 The compounds identified through the screening method hereby described are within the scope of the present invention. Such compounds are preferably low molecular weight molecules of peptidic or non-peptidic nature. Thanks to their small size they are more practical for use for medicinal purposes, compared to angiostatin. These molecules and the uses thereof are described in more detail below.

20 The proteins and peptides according to the invention may be synthesized using standard chemical peptide synthesis techniques. For solid phase synthesis, see e.g. Barany and Merrifield, *Solid-Phase Peptide Synthesis*, pp 3-284 in *The Peptides: Analysis, Synthesis Biology*, Vol. 2: *Special Methods in Peptide Synthesis*, Part A.

Preferably, the proteins, peptides and polypeptides according to the invention are  
25 synthesized using recombinant DNA methodology, which generally involves creating a DNA sequence that encodes the protein or peptide, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein or peptide in a host, isolating the expressed protein or peptide and, if required, renaturing the product. Once expressed, the recombinant peptides or proteins can be purified according to standard  
30 procedures in the art. Thus, another aspect of the present invention is a vector, such as a virus or a plasmid, comprising a nucleic acid according to the invention. Further, the invention also encompasses a recombinant cell transformed or transfected with the said

vector expressing the present protein or peptide as well as a recombinant cell expressing the present antibody, which will be defined in more detail below. Vectors encoding the peptides and proteins according to the invention are useful in expressing those molecules to provide immunogens for antibody production. The vectors according to the invention are also useful  
5 for transforming cells *in vitro* or *in vivo* to express the present peptides and proteins. Cells expressing any one of the present nucleic acids, such as the gene defined by SEQ ID NO 1, may be used in a wide variety of contexts and are also within the scope of the present invention. Such cells may be eucaryotic or procaryotic.

The proteins and peptides according to the invention can be used as antigens for  
10 raising antibodies against the same. Consequently, the invention also encompasses an antibody which specifically binds a peptide according to the invention. Such antibodies are useful for immunoassays, e.g. for the isolation of peptides or polypeptides. The peptides according to the invention may also be used in assays, such as amplification specific assays, immunological assays *etc.*

15 The antibodies according to the invention may be monoclonal or polyclonal and include individual, allelic, strain or species variants, or fragments thereof, both in their naturally occurring (full-length) forms and recombinant forms. Additionally, the antibodies are raised to the present peptides or polypeptides in either their native configuration or in non-native configurations. Anti-idiotypic antibodies can also be generated. Many methods  
20 of making antibodies are known to persons skilled in the art. For techniques for preparing monoclonal antibodies, see e.g. Stittes et al (eds.), *Basic and Clinical Immunology* (4<sup>th</sup> ed), Lange Medical Publications, Los Altos, CA, and references cited therein. For techniques that involve selection of libraries of recombinant antibodies in phage or similar vectors, see e.g. Huse et al. (1989) *Science* 246:1275-1281.

25 The molecules according to the invention may be used in pharmaceutical preparations, especially for the treatment and/or prevention of angiogenesis related disorders. Accordingly, the invention relates to a peptide, polypeptide, protein or antibody according to the invention for use as a medicament as well as to the use of said molecules in the manufacture of a medicament directed towards an angiogenesis related disease or disorder.  
30 The invention also relates to a pharmacological preparation comprising a molecule according to the invention together with a pharmaceutically acceptable carrier. The molecules used as medicaments according to the invention may be anyone of the above

described peptides, polypeptides, proteins or antibodies as well as any novel substance identified in a screening method using the same and described above.

Accordingly, the most preferred use of the present molecules is in assays, wherein novel substances are screened for. Compounds may be identified which exhibit similar anti-angiogenic effects as angiostatin and/or kringle 5, but which are smaller, more efficient and preferably exhibits a longer half time in a human or animal body than angiostatin. The shorter half time may be due to a lower tendency to be degraded by proteases. When an organic compound is designed, a molecule according to the invention is used as a "lead" compound. The design of mimetics to known pharmaceutically active compounds is a well known approach in the development of pharmaceuticals based on such "lead" compounds. Mimetic design, synthesis and testing are generally used to avoid randomly screening a large number of molecules for a target property.

Thus, such novel molecules are preferably used as medicaments that may be administered in much lower doses than angiostatin, and which may be administered less frequently, such as *e.g.* once every fourteen days, which is to be compared to the half time of angiostatin which is about ten times shorter. In a particular embodiment, the novel molecules identified by the screening methods according to the invention are low molecular weight organic molecules, in which case a pharmaceutical preparation may be prepared thereof for oral intake, such as in tablets.

The pharmaceutical preparations according to the invention may however be prepared for any route of administration, *e.g.* oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular or intraperitoneal. The nature of the carrier or other ingredients will depend on the specific route of administration. (Examples of techniques and protocols that are useful in this context are *inter alia* found in Remington's Pharmaceutical Sciences, 16<sup>th</sup> edition, Osol, A (ed.), 1980.)

The dosage of these low molecular weight compounds will depend on the disease state or condition to be treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. For treating human or animals, between approximately 0.5 mg/Kg of body weight to 500 mg/Kg of body weight of the compound can be administered.

The present compounds and methods are advantageously used in relation to all kind of angiogenesis related disorders and/or diseases, such as tumor conditions, diabetes,

rheumatoid arthritis and even some inflammatory diseases, such as psoriasis, chronic inflammations of the intestines, asthma etc. It is also suggested that they may be used in order to treat and cure, or prevent, obesity.

In a particular embodiment, the present molecules are used in gene therapy. For a  
5 review of gene therapy procedures, see e.g. Anderson, *Science* (1992) 256:808-813.

A further advantageous use of the present invention is to develop methods of regulating the signalling of the present angiostatin and/or kringle 5 receptor in the body and therefore, the invention also relates to methods of treating a human or animal patient suffering from an angiogenesis related disease or disorder as well as to methods preventing  
10 such conditions.

### EXPERIMENTAL

Below, the invention will be disclosed in more detail with reference to the drawings.

All references in the present disclosure and above are hereby incorporated in the  
15 present application.

#### *Evidence that angiostatin binds to endothelial cells*

By competitive binding assays between angiostatin and the angiogenic factors, VEGF and bFGF, the present inventors have shown that angiostatin does not affect the ligand-  
20 receptor interaction of these molecules. The same level of binding could be detected in the presence or absence of unlabeled angiostatin. Thus, it can be ruled out that angiostatin acts by blocking angiogenic factors interaction with endothelial cells.

The direct binding of angiostatin and its precursor plasminogen has been studied by binding assays using iodinated proteins and analyzing their interaction with bovine  
25 microcapillary endothelial cells, see Figure 1.

In particular, human angiostatin (kringle domains 1-4) or plasminogen was labeled with iodine 125 by the Iodogen method according to the protocol of the manufacturer (Pierce Inc.). The labelled protein was then purified on a G50 sepharose column (Pharmacia Inc.) The specific activity was estimated at 90 000 cpm/ng protein. For binding assays,  
30 bovine capillary endothelial cells were grown to confluency in 12 well plates. The cells were washed with PBS containing 1mg/ml bovine serum albumine (BSA). The cells were then incubated with 10ng/ml radio-labeled angiostatin or plasminogen. The binding was

competed with increasing concentrations of unlabeled ligand. Cells were incubated on ice for 2 hours. Cells were then washed five times with PBS+1mg/ml BSA. The cells were lysed with 1% Triton X100 in PBS and radioactivity was measured in a gamma counter. Dissociation constant and receptor numbers were estimated using the RBINDING program  
 5 (van Zoelen EJ. Anal. Biochem. 1992 Feb 1;200 (2):393-9).

**Identification of angiostatin binding molecules using the yeast two hybrid system**

Angiostatin retains activity even after reduction, suggesting that three dimensional folding is not vital for binding and activity. This favours screening procedures wherein a  
 10 large number of clones may be screened although protein refolding may be less accurate.

The yeast two hybrid system was employed to screen for molecules that bind kringle domains 1-4 of plasminogen. This is further disclosed below with reference to figure 2. Approximately  $2 \times 10^6$  clones from a two hybrid cDNA library from human term placenta (Stratagene) were screened. Positives clones were identified in the following way:

15 (1) Screening under selective conditions (His-, Leu- and Trp-) generated 37 positive clones in yeast strain CG1945.

(2) Seven out of 37 clones displayed high  $\beta$ -galactosidase activity after incubation with ONPG (SIGMA) at 30°C for 2h.

20 (3) The DNA from the seven colonies that contained high  $\beta$ -gal activity was purified and retransfected into yeast strain Y190. Three out of the seven colonies retained activity in the new yeast strain. Sequencing analysis of these clones revealed that they were derived from the same gene.

25 (4) Growth in the presence of 50mM 3-aminotriazol (Fig. 3) as well as  $\beta$ -gal activity (see table below) was assessed in Big 3 clones and compared to positive and negative controls.

Binding Domain	Activation Domain	$\beta$ -Gal Activity
Angiostatin + Binding Domain	Big3 - Activation Domain	15 u
Angiostatin + Binding Domain	Activation Domain alone	<0.04 u
Binding Domain alone	Big3 - Activation Domain	0.07 u
p53 + Binding Domain	Big3 - Activation Domain	0.05 u
p53 + Binding Domain	SV40LT - Activation Domain	90 u

Sequence of Big 3 (angiostatin-binding domain)

After isolation of the big 3 clone from a placenta yeast two-hybrid library (Stratagene, Inc.), we directly sequenced the cDNA insert from the pGAD activation domain vector with GAL4 AD sequencing primers. The cDNA insert was recloned into pUC18 vector using  
 5 EcoRI sites from adaptors and sequencing was repeated using universal and reverse primers. Sequences were analyzed in an ALF automated sequencer (Pharmacia). The sequence of Big 3 is shown in SEQ ID NO. 4.

Expression and purification of Big3 and Big3-GST fusion protein

10 Big3 sequence has been expressed in *E.coli* as fusion protein with the glutathione S - transferase (GST) domain from *Schistosoma japonicum*.

•*Vector construction:*

Big3 fragment (429 bp) was obtained by PCR amplification using pUC18-Big3 plasmid as template. Primer sequences were:

15 BamHI-NH<sub>2</sub> 5' TAC GGA TCC GAA TCG AAC AAA ACT GCA GCT G 3' (SEQ ID NO. 5)

XhoI-COOH 5' ATA CTC GAG TCA TGG AGC TGG AGT TGG AGC CA 3' (SEQ ID NO. 6)

The cycling protocol used was:

20	94°C 3', 60°C 1', 72°C 1'	1 cycle
	94°C 30'', 60°C 1', 72°C 2'	30 cycles
	94°C 30'', 60°C 1', 72°C 5'	1 cycle

Taq polymerase: native Pfu DNA polymerase (Stratagene)

25 PCR fragment was digested with BamHI and XhoI, purified and ligated to PGEX-6P-2 plasmid (Pharmacia Biotech) digested with the same restriction enzymes. Ligation mixture was used to transform XL1-Blue cells (Stratagene). Recombinant plasmids were verified by restriction analysis and automated sequencing.

•*Expression and purification:*

30 DH5α cells (Clontech) were transformed with one verified clone, named pGEX-Big3, and induced for 6 hours, room temperature with 0.1 mM IPTG.

The fermentation broth was centrifuged at 4000xrpm 15 min and the cell pellet was resuspended in 10% w/v of lysis buffer (50 mM TRIS.HCl pH 8.0, 100 mM NaCl, 20 mM

DTT, 1 mM EDTA, protease inhibitor mix), and lysed by sonication. The total lysate was centrifuged at 15000 xg for 20 min at 4°C. The clarified supernatant was applied to a Glutathione-Sepharose column (1ml for 20 ml of lysate) preequilibrated with lysis buffer. The resin was washed with 10 column volumes (CV) of lysis buffer and the fusion protein  
5 was eluted with 3 CV of elution buffer (100 mM TRIS.HCl pH 8.0 20 mM reduced glutathione).

GST-Big3 protein can be cleaved by incubation of the glutathione-Sepharose bound fusion protein with 20 ul/ml resin of PreScission protease in PS buffer containing 50 mM TRIS.HCl pH 7.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF.

10 The eluted proteins behave like a single peak in rp-HPLC (10-90% gradient of acetonitrile in water plus 0.1% TFA), show the expected molecular size by mass analysis (electrospray) and the correct NH2 sequence. In SDS-PAGE a contaminant appears at the apparent MW of 80 kD; it was demonstrated to be DnaK, a bacterial chaperone, which can be eliminated running an ion exchange chromatography on a HiTrapQ column.

15 The yields obtained from 1 litre of fermentation are about 10 mg of GST-Big3 fusion protein and about 3 mg of the cleaved Big3.

#### *In vitro binding of recombinant GST-tagged Big 3 to angiostatin*

The protocol used for binding is described here below.

20 One colony of pGEX-Big3 transformant was inoculated into 10 ml LB medium plus ampicillin and grown overnight at 37°C.

The overnight culture was diluted 1:10 into 100 ml fresh medium and after 1 hour of incubation at 37°C, IPTG was added to a final concentration of 0.5mM and incubation continued for 3 to 7 hours.

25 The culture was then centrifuged at 5000g for 10 minutes, the pellet was resuspended in 3-5 ml of ice-cold PBS and cells were lysed by sonication. Triton X100 was added to a final concentration of 0.5 - 1 % and 1.5 ml aliquots of the suspension were centrifuged at 14000 rpm for 10 minutes.

30 0.1-0.3ml of 50% slurry of glutathione-agarose beads were added to the supernatant and mixed for 3-5 hour at 4°C. The beads were then collected by centrifugation and washed 5 times with ice-cold PBS and 2 times with binding solution (B.S.) consisting of: 50mM Tris pH7.5, 150mM NaCl, 0.5mM EDTA, 1mM DTT, 1mM PMSF).



Binding assay: 0.7ml B.S., 0.1% calf serum, 500ng angiostatin were mixed with 30-50µl 50% slurry of Big3-immobilized glutathione-agarose beads for 1 - 3 hour at 4°C.

The resin was washed 5-7 times with ice cold B.S., then used for Western blot analysis using anti-human plasminogen antibodies (Dako Inc.).

- 5        Figure 4 shows how purified recombinant Big 3 binds angiostatin in vitro. Interestingly, binding of plasminogen could also be detected, but only after reduction of disulphide bonds by treating it with DTT.

10        Cloning of full-length sequence

- Figure 5 illustrates the scheme for cloning the full-length sequence of ABP-1. The whole gene was cloned by screening a placenta cDNA phage library with a Big3 probe (with repetitive sequences removed) together with 5'RACE PCR (Gibco) using mRNA from human umbilical cord endothelial cells. The full sequence of the cDNA clone is disclosed in SEQ ID NO. 1, whereas the encoded protein is shown in SEQ ID NO. 2. Details of the experimental protocol are as follows.

- 10 million clones of a placenta lambda phage library (Stratagene, Inc.) were screened using a *Hin*/I fragment of Big 3 as probe. DNA isolation and Southern blot procedures were performed according to established protocols (Sambrook et al 1989). We isolated 5 clones (7-1, 7-2, 8-2, 9-3, 9-5) with sequences that overlap with Big3. The 5'-sequence of the 7-2 clone was used for designing Gene-Specific Primers (GSP) for 5'RACE PCR (Gibco Life technologies, Inc.). mRNA isolated from Human umbilical cord endothelial cells was used to identify 5' sequences.

Primers used for the first RACE PCR:

- 25        Primers: GSP1- (5' to 3') GCTGACAGTTGCCCTGACGCTGCT (SEQ ID NO. 10)  
              GSP2- (5' to 3') CGGAGACGGTGCTCTAGCTGCTCA (SEQ ID NO. 11)  
              GSP3- (5' to 3') TCCTTCCAACCTTGCCTCAAGTTCCG (SEQ ID NO. 12)

- RACE procedures have been used for amplification and cloning unknown sequences between the GSP2 and GSP3 and the 5'-end of the mRNA ABP-1. This sequence was then used to design new primers for the next set of RACE PCR:

Primers: GSP1-(5' to 3') GGTGGCAGCGGACAGGCAGGATAC (SEQ ID NO. 13)

GSP2 GAGGCGGAGAGAACTAAGAGAAGA (SEQ ID NO. 14)

GSP3 GAGCGGAGATGGAGGAGTAATTCA (SEQ ID NO. 15)

5 Clones A2-2, A2-1 and A1-C with overlapping sequences were isolated. The A2-1 sequence was used as probe for the second screening of the placenta phage library. From this screening we isolated another 2 clones (7-10 and 6-5). As shown in Figure 6, of the six possible frame the only one producing a complete open reading frame is frame 2, yielding a putative protein of 675 amino acid residues.

10

#### mRNA Expression pattern

A commercially (Clontech, Inc.) obtained multiple human adult and fetal tissue (#7760-1 and #7756-1) mRNA blots (2mg mRNA/well) was probed for ABP-1. The blots were hybridized with the ExpressHyb hybridization solution (Clontech, Inc.) according to the protocol of the manufacturer. The blots were probed with the 7-2 5'PstI fragment. Figure 7 shows the results of the experiment; sizes are 9.5 and 7.5 kb.

15

ABP-1 was also detected in human umbilical cord, bovine aortic and bovine microcapillary endothelial cells. Little or no expression was detected in the immortalized endothelial cell-line EaHy926 and in human fetal fibroblasts. Neither of the cell lines respond to angiostatin or exhibit any binding of FITC-labeled angiostatin.

20

#### Real time RT-PCR

The 5' nuclease assay (TaqMan assay) uses a nonextendable oligonucleotide hybridization probe (TaqMan Probe). The TaqMan probe consists of an oligonucleotide with a 5'-reporter dye and a 3'-quencher dye. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence, primarily by a Foster-type energy transfer. During PCR, forward and reverse primers hybridize to a specific sequence of the target DNA. The TaqMan probe hybridizes to a target sequence within the PCR product. The Taq Polymerase cleaves the TaqMan probe with its 5'-3' nuclease activity. The reporter dye and quencher dye are separated upon cleavage, resulting in increased fluorescence of the reporter.

25

30

Real time RT-PCR analysisRNA Preparation

- 5 Isolation and purification of total RNA from tissues and cells listed below was performed using the Ultraspec RNA isolation system (Biotex).

HDMEC/2	h.dermal microvascular EC	poly A+
A2780	h.ovarian carcinoma	TOTAL
A375	h. melanoma	TOTAL
HDF	H.dermal fibroblasts	TOTAL
HELA	h.cervix carcinoma	TOTAL
DUI45	h.prostate carcinoma	TOTAL
HUVEC	h.umbelical vein EC	TOTAL
ECV304	immortalized EC	TOTAL
CEM	h.acutelymphobl.leuk.	TOTAL
K562	h.erythroleukemia	TOTAL
JURKAT	h.acuteT-cellleukemia	TOTAL
THP-1	h.monocyte(acute leu)	TOTAL
EaHy926	h.dermal cells	TOTAL
S35/K9	human colon cancer	TOTAL
Brain	human normal tissue	TOTAL
Colon	human normal tissue	TOTAL
Prostate	human normal tissue	TOTAL
Skel.Muscle	human normal tissue	TOTAL
Uterus	human normal tissue	TOTAL
Placenta	human normal tissue	TOTAL

The RT reaction was performed using TaqMan Reverse Transcription Reagent (PE Applied Biosystems) with Random hexamers, as RT primers. The reaction volume for Reverse Transcription step was 100 µl and the total RNA amount was 1 µg for sample.

The RT was performed using the following cycling parameter:

5

10' at 25°C

45' at 48°C

5' at 95°C

10

#### PCR reaction

After a primer concentration optimization, the PCR reaction on 10 ng of the cDNA was performed using TaqMan Universal PCR Master Mix (PE Applied Biosystems) and the following oligonucleotides

• ABP-1 Forward Primer: 5' GTTTGACCTGCAATCCAGACAA 3' (SEQ ID NO. 7) Final concentration 300nM

• ABP-1 Reverse Primer: 5' CCCAGGATCTGAATGGGAGTT 3' (SEQ ID NO. 8) Final concentration 900nm

• ABP-1 TaqMan Probe:  
5' (FAM dye)-CAGATGGGCCTGTGTTCCACTCCAA-(TAMRA dye) 3' (SEQ ID NO. 9) Final probe concentration 200nM

20

The cycling protocols was:

2' at 50°C; 10' at 95°C 1 cycle

15'' at 95°C; 1' at 60°C 40 cycles

25

#### Relative Quantitation of gene expression

The Comparative method use an arithmetic formula to achieve the result for relative quantitation without need for Standard curve.

The result, depicted in Figure 8, indicate how many fold the sample X expresses the target relative to the Calibrator which is the sample that shows the lowest level of expression of the target. In this experiment EaHY926 sample was chosen as calibrator.

30

### Antibodies against Big-3

For immunisation of New Zealand White rabbits, 100 micrograms of Big3-GST fusion protein were dissolved in 1 ml phosphate buffered saline (PBS) homogenised with 1 ml of Freund's Complete Adjuvant (Gibco). The resulting emulsion was injected  
5 subcutaneously on day 0 and this treatment was repeated on days 15 and 28. Blood was removed from rabbits on day 35, allowed to coagulate overnight at 4°C. and the resulting serum stored at -20°C.

For purification of specific antibodies, resin-immobilised ligand was produced as follows: Big3 polypeptide was diluted in 0.1M sodium bicarbonate, 0.5 M NaCl, pH8.3, at  
10 a concentration of 5 mg/ml in a total volume of 2 ml. This was reacted for two hours at room temperature with 2 ml of cyanogen bromide-activated Sepharose CL-4B resin (Sigma Chemical Co. St Louis, MO). After reaction, the resin was washed three times in 10 volumes of 100 mM Tris, 500 mM NaCl, pH 7.5. Immune serum was incubated with the affinity resin for two hours at 4°C, after which resin was washed in a 5 ml glass  
15 chromatography column (Bio-Rad, Richmond CA) for with 25 volumes of 100 mM Tris, 500 mM NaCl, pH 7.5. Specific antibodies were eluted in 1 ml aliquots with 100 mM Glycine/HCl, pH 2.8. Elution of antibody was followed by monitoring the optical density at 280 nm (OD280), and fractions with an OD280 of greater than 1 were pooled and dialysed (Slide-A-lyzer cassettes, Pierce) for 36 hours at 4°C against 1 liter PBS, with three changes  
20 of buffer.

### Binding and signalling of angiostatin via the ABP-1 protein

Figures 9A and 9B show data of binding of FITC-labeled angiostatin to ABP-1 transfected HeLa and EaHy926 cells transfected with the vector control. In particular figure  
25 9A shows the cellular localization of ABP-1 fused to green fluorescent protein (GFP) in transiently transfected cells. The protein can be detected in the endoplasmic reticulum and the cell membrane. DABP-1 contains a 500bp deletion in the 5' end of the gene, which disrupts the previously described localization of ABP-1.

Figure 9B shows HeLa cells transfected with ABP-1 GFP. Incubation with 2.5 mg of  
30 angiostatin for 60 minutes at 0°C and subsequent incubation for 15 minutes at 37°C induces internalization of ABP-1-GFP.

Figure 9C shows the binding of angiostatin to ABP-1. We have shown that fluorescein isothiocyanate (FITC)-labelled angiostatin binds specifically to endothelial cells (data not shown). We have transfected HeLa cells with either the ABP-1 expression construct or the vector control (p RC/CMV, In Vitrogen, Inc.). We incubated live HeLa cells FITC-labelled angiostatin (10ug/ml) in DMEM+10% fetal calf serum at 0°C for 60 minutes. The cells were then incubated at 37°C at 15 minutes to aggregate bound angiostatin. Binding was analyzed with a fluorescent microscope. Binding of angiostatin was detected in ABP-1 transfected cells but not in the vector control.

Figure 9D shows immunostaining of ABP-1 in Human umbilical cord endothelial (HUVE) cells together with staining against F-actin with rhodamin-labelled phalloidin.

*•Immunostaining protocol:*

HUVE cells were fixed in 4 % formaldehyde, washed in PBS and preblocked in 5% horse serum. The blocking solution was removed and replaced by rabbit polyclonal antibodies against the angiostatin-binding domain Big3 diluted in 5% horse serum. Positive staining was visualized with a fluorescence-labeled secondary antibody (Dako, Inc.). Rhodamin-conjugated phalloidin (Molecular Probes, Inc.) was stained simultaneously with the secondary antibody (after permeabilization with 1%triton X100 for 1 minute). Rabbit polyclonal antibodies against green fluorescent protein was used as a negative control. In addition no positive staining could be detected in human fibroblasts.

As can be seen in Fig. 9D, ABP-1 is localized in focal adhesions and membrane ruffles (arrows).

**In vitro kinase data**

Huve cells were plated subconfluent in 5cm Petri dishes. Angiostatin was added at 2.5 mg/ml at different time points the following day. All plates including controls were harvested simultaneously. The cells were rinsed in ice cold PBS and incubated in 1ml lysis buffer. The cells were transferred to an eppendorf tube and centrifuged at 14 000rpm for 5 minutes at 4°C. The supernatant was transferred to another eppendorf tube and 2µg of Big 3 rabbit polyclonal antibodies was added. The samples were incubated for 60 min. at 4°C and subsequently 50µl of a protein A sepharose (Pharmacia, Inc.) slurry was added and incubated for another 60 min. in a rotating incubator. The immunoprecipitates were collected by brief centrifugation and washed two times in lysis buffer, once in washing

buffer and once in kinase buffer. Residual buffer was removed with a syringe. 25 µl of kinase buffer was added to each tube together with 1µCi gammaATP (Amersham, Inc.). The samples were incubated at R.T. for 20 minutes. The reaction was stopped by adding 2xSDS PAGE sample buffer. The samples were boiled under denaturing conditions and subsequently analyzed by SDS PAGE.

The data illustrated in Figure 10 show that addition of angiostatin downregulates ABP-1 associated kinase activity within 30 minutes. This is direct proof that angiostatin affects signalling pathways that are mediated by ABP-1.

10      *ABP-1 mediates Angiostatin-induced focal adhesion kinase activity.*

The data illustrated by Figure 11 show that addition of 2.5 µg/ml of angiostatin upregulates FAK activity within 1 hour after addition.

EaHy926 cells were plated subconfluent in 5cm Petri dishes. Angiostatin was added at 2.5 µg/ml at different time points the following day. All plates including controls were harvested simultaneously. The cells were rinsed in ice cold PBS and incubated in 1ml lysis buffer. The cells were transferred to an eppendorf tube and centrifuged at 14 000rpm for 5 minutes at 4°C. The supernatant was transferred to another eppendorf tube and 1µg of FAK monoclonal antibody (Transduction Lab. Inc.) was added. The samples were incubated for 60 min. at 4°C and subsequently rabbit anti-mouse IgG + 50µl of a protein A sepharose (Pharmacia, Inc.) slurry was added and incubated for another 60 min. in a rotating incubator. The immunoprecipitates were collected by brief centrifugation and washed two times in lysis buffer, once in washing buffer and once in kinase buffer. Residual buffer was removed with a syringe. 25 µl of kinase buffer was added to each tube together with 1µCi γATP (Amersham, Inc.). The samples were incubated at R.T. for 20 minutes. The reaction was stopped by adding 2xSDS PAGE sample buffer. The samples were boiled under denaturing conditions and subsequently analyzed by SDS PAGE.

As can be seen in Fig. 11, addition of angiostatin upregulates FAK activity within 1 hour. It should be noted that EaHy926 cells are not expressing ABP1 as demonstrated by reverse transcriptase PCR analysis.

## CLAIMS

1. An isolated human angiogenesis-associated protein capable of binding an N-terminal fragment of plasminogen.
- 5 2. The protein of claim 1 wherein the N-terminal fragment of plasminogen is constituted by the kringle domains 1 to 4 of plasminogen.
3. The protein of claim 1 or 2 comprising an amino acid sequence having at least approximately 80% sequence homology, preferably approximately 90% sequence homology, more preferably approximately 95% sequence homology and most preferably  
10 approximately 98% sequence homology to SEQ ID NOs. 2, 3 or 4.
4. The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 2.
5. The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 3, wherein the amino acid residue in position 135 is Asn, Ser or Asp and the three  
15 amino acid residues in positions 148 to 150 are the tripeptide Glu-Leu-Ala or the tripeptide Thr-Trp-Pro.
6. The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 4.
7. A peptide capable of binding an N-terminal fragment of plasminogen and which  
20 has an amino acid sequence comprising at least 5 contiguous amino acid residues of SEQ ID NO. 2.
8. A peptide according to claim 7 which has an amino acid sequence comprising at least 10 contiguous amino acid residues of SEQ ID NO. 2.
9. An isolated nucleic acid molecule comprising a sequence that codes for a  
25 protein or peptide according to any one of claims 3 to 8.
10. The isolated nucleic acid molecule of claim 9 encoding the protein of claim 4.
11. The isolated nucleic acid molecule of claim 9 encoding the protein of claim 5.
12. The isolated nucleic acid molecule of claim 9 encoding the protein of claim 6.
13. The isolated nucleic acid molecule of any one of claims 10 to 12 comprising at  
30 least the sequence from nucleotide 2177 to nucleotide 2608 of SEQ ID NO. 1.
14. The isolated nucleic acid molecule of claim 9 comprising the sequence from nucleotide 797 to nucleotide 2824 of SEQ ID NO. 1.



15. The isolated nucleic acid molecule of claim 14 consisting of the sequence of SEQ ID NO.1.
16. A nucleic acid molecule encoding a peptide according to claim 7 or 8.
- 5 17. A nucleic acid capable of specifically hybridizing, under stringent conditions, to a nucleic acid according to claim 9 to 16.
18. A vector comprising a nucleic acid according to any one of claims 9 to 17.
19. The vector of claim 18 which is a plasmid.
20. The vector of claim 18 which is a virus.
- 10 21. A recombinant cell transformed or transfected with the vector of claim 18.
22. An antibody or antibody fragment which specifically binds a protein or peptide according to any one of claims 3 to 8.
23. An antibody according to claim 22 which is a monoclonal antibody or fragment thereof.
- 15 24. The antibody of claims 22 or 23 for use as a medicament.
25. A recombinant cell expressing the antibody according to claims 22 or 23.
26. A screening method for identifying a compound capable of interacting with a protein according to any one of claims 1 to 6.
27. A compound identified through the screening method of claim 26.
- 20 28. The proteins, peptides or compounds of any one of claims 1 to 8 and 27 for use as a medicament.
29. Use of the proteins, peptides or compounds according to any one of claims 1 to 8 and 27 in the manufacture of a medicament directed towards an angiogenesis-related disease or disorder.
- 25 30. A pharmaceutical preparation comprising a protein, peptide or compound according to any one of claims 1 to 8 and 27 together with a pharmaceutically acceptable carrier.




Fig. 1

2/12





Fig. 2

**-His, +3-AT**



**Fig. 3**

<u>Angiostatin</u>	<u>Plasminogen</u>
Big-3 R0	Big-3 R0



Fig. 4

5/12




Fig. 5




Fig. 6




Fig. 7










Fig. 8

**Fig. 9A****Fig. 9B****Fig. 9C**



**Fig. 9D**




Fig. 10

12/12




Fig. 11

## SEQUENCE LISTING

<110> Pharmacia & Upjohn

<120> Angiogenesis related molecules

<130> pctpha1856

<140>

<141>

<150> SE9804372-2

<151> 1998-12-17

<160> 15

<170> ParentIn Ver. 2.1

<210> 1

<211> 6463

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (797) .. (2824)

<400> 1

ccaggagctg ccttggcagt cacgcccctt ccttcgagg agctttctgg ctgcctaaac 60  
tggtagaccc cctgaattac tcctccatct ccgctctctt tcgcctcttc ttctcttagt 120  
tctctccgcc tccccctcaa ctaccaccac ctccagtcag tctcgctctc ggctatccgc 180  
tgctccaccc tctggcccggt tatcctgcct gtcgctgcc accaaggaga gcccgagcgg 240  
agcagcgagg aggggagcag ccgggagttg gggcttcccc cctgcccata cctggccgct 300  
ggcccgggac cgaagccact tgagcgagca gagagtcgtc acctgtctt ctttgccttc 360  
agggagctgc taagaaggac aaataagata gcagagtgaag agagcttttg tctccttaga 420  
aggaaggctg agaaactaaa ggccagcgca ggacatctca ttgccattgt cagccaggaa 480  
ctcgagcct cacagcccta cttcttctct gacctctggg gggctcttgc ccttgctaca 540  
atctccacca tccactagat tgtctcttgc ccgacacccc ttggteccaa accagggaga 600  
ccattcagct cacctgccta ggccgcagca gcatttcctt cctaatacagg ctcaccaggg 660  
ggatcattac cgtctctccc aacctggcct gaggcagcag cagcagcaac agcagcagca 720

gcaccatcat caccatcacc accaacaaca gcagcagcag cagccacagc agcagccagg 780

agaagcctat tcagct atg cct cgg gct cag cca tcc tct gct tct tat cag 832  
Met Pro Arg Ala Gln Pro Ser Ser Ala Ser Tyr Gln  
1 5 10

cca gtg cca gca gac cct ttt gcc att gtt tcc aga gcc cag cag atg 880  
Pro Val Pro Ala Asp Pro Phe Ala Ile Val Ser Arg Ala Gln Gln Met  
15 20 25

gtt gag atc ctc tca gac gag aac cgg aac ttg agg caa gag ttg gaa 928  
Val Glu Ile Leu Ser Asp Glu Asn Arg Asn Leu Arg Gln Glu Leu Glu  
30 35 40

gga tgc tat gag aag gtg gca aga ctg cag aag gtg gag aca gaa atc 976  
Gly Cys Tyr Glu Lys Val Ala Arg Leu Gln Lys Val Glu Thr Glu Ile  
45 50 55 60

cag cgc gtc tcg gag gca tat gag aac ctc gtg aag tca tcc tcc aaa 1024  
Gln Arg Val Ser Glu Ala Tyr Glu Asn Leu Val Lys Ser Ser Ser Lys  
65 70 75

aga gag gcc cta gag aaa gcc atg aga aac aag cta gag ggc gag att 1072  
Arg Glu Ala Leu Glu Lys Ala Met Arg Asn Lys Leu Glu Gly Glu Ile  
80 85 90

cgg agg atg cat gat ttc aac agg gat ctg aga gag cgt cta gag act 1120  
Arg Arg Met His Asp Phe Asn Arg Asp Leu Arg Glu Arg Leu Glu Thr  
95 100 105

gcc aac aag cag ctt gca gag aag gaa tat gag ggg tca gag gac acc 1168  
Ala Asn Lys Gln Leu Ala Glu Lys Glu Tyr Glu Gly Ser Glu Asp Thr  
110 115 120

aga aaa acc atc tcg cag ctc ttt gca aaa aat aaa gaa agc cag cgt 1216  
Arg Lys Thr Ile Ser Gln Leu Phe Ala Lys Asn Lys Glu Ser Gln Arg  
125 130 135 140

gag aag gag aag ctg gaa gcg gag ctg gcc act gcc cgt tct acc aat 1264  
Glu Lys Glu Lys Leu Glu Ala Glu Leu Ala Thr Ala Arg Ser Thr Asn  
145 150 155

gag gac caa aga cga cac atc gaa atc cga gat cag gcc ctg agt aat 1312  
Glu Asp Gln Arg Arg His Ile Glu Ile Arg Asp Gln Ala Leu Ser Asn  
160 165 170

gcc cag gcc aag gtg gta aag ctg gaa gaa gag ctg aaa aag aag caa 1360  
Ala Gln Ala Lys Val Val Lys Leu Glu Glu Glu Leu Lys Lys Lys Gln  
175 180 185

gtg tac gtt gac aag gtg gag aag atg cag cag gcc ctt gta cag ctc	1408
Val Tyr Val Asp Lys Val Glu Lys Met Gln Gln Ala Leu Val Gln Leu	
190 195 200	
cag gca gca tgt gaa aaa cgt gag cag cta gag cac cgt ctc egg aca	1456
Gln Ala Ala Cys Glu Lys Arg Glu Gln Leu Glu His Arg Leu Arg Thr	
205 210 215 220	
cga ctg gag agg gaa ctg gaa tcc ctg aga atc cag cag cgt cag ggc	1504
Arg Leu Glu Arg Glu Leu Glu Ser Leu Arg Ile Gln Gln Arg Gln Gly	
225 230 235	
aac tgt cag ccc acc aac gtt tca gaa tac aat gct gcc gca ctg atg	1552
Asn Cys Gln Pro Thr Asn Val Ser Glu Tyr Asn Ala Ala Ala Leu Met	
240 245 250	
gag ctc ctt cgg gag aaa gag gag agg att ctg gct ctg gaa gct gat	1600
Glu Leu Leu Arg Glu Lys Glu Glu Arg Ile Leu Ala Leu Glu Ala Asp	
255 260 265	
atg aca aag tgg gag cag aaa tat ttg gag gag aat gtg atg aga cat	1648
Met Thr Lys Trp Glu Gln Lys Tyr Leu Glu Glu Asn Val Met Arg His	
270 275 280	
ttt gct ctg gat gct gct gca act gtg gct gct cag agg gac aca aca	1696
Phe Ala Leu Asp Ala Ala Ala Thr Val Ala Ala Gln Arg Asp Thr Thr	
285 290 295 300	
gtc atc agt cac tct cct aac acc agc tat gac aca gct cta gaa gct	1744
Val Ile Ser His Ser Pro Asn Thr Ser Tyr Asp Thr Ala Leu Glu Ala	
305 310 315	
cgc atc cag aaa gag gag gaa gaa atc ttg atg gcc aat aag cgt tgc	1792
Arg Ile Gln Lys Glu Glu Glu Glu Ile Leu Met Ala Asn Lys Arg Cys	
320 325 330	
ctt gac atg gag ggc agg att aag acc ctc cat gcc cag att att gag	1840
Leu Asp Met Glu Gly Arg Ile Lys Thr Leu His Ala Gln Ile Ile Glu	
335 340 345	
aag gat gcc atg atc aaa gta ctc cag cag cgt tcc cgg aag gag ccg	1888
Lys Asp Ala Met Ile Lys Val Leu Gln Gln Arg Ser Arg Lys Glu Pro	
350 355 360	
agc aag aca gag cag ctg tgc tgc atg cgg cca gcg aag tct ctg atg	1936
Ser Lys Thr Glu Gln Leu Ser Cys Met Arg Pro Ala Lys Ser Leu Met	
365 370 375 380	
tcc att tcc aat gct gga tca ggc ttg ctc tcc cac tca tcc acc ctg	1984
Ser Ile Ser Asn Ala Gly Ser Gly Leu Leu Ser His Ser Ser Thr Leu	
385 390 395	



act ggc tcc ccc atc atg gaa gaa aag cga gac gac aag agc tgg aag	2032
Thr Gly Ser Pro Ile Met Glu Glu Lys Arg Asp Asp Lys Ser Trp Lys	
400 405 410	
ggg agc cta ggc att ctc ctg ggt gga gac tac cgt gct gaa tat gtc	2080
Gly Ser Leu Gly Ile Leu Leu Gly Gly Asp Tyr Arg Ala Glu Tyr Val	
415 420 425	
cct tcc aca ccc tcg cct gtg cca ccc tcg act ccc ctg ctc tcg gct	2128
Pro Ser Thr Pro Ser Pro Val Pro Pro Ser Thr Pro Leu Leu Ser Ala	
430 435 440	
cac tcc aag aca ggc agc cga gac tgc agt acc caa act gaa cgt ggg	2176
His Ser Lys Thr Gly Ser Arg Asp Cys Ser Thr Gln Thr Glu Arg Gly	
445 450 455 460	
acg gaa tcg aac aaa act gca gct gtt gct ccc atc tct gtt cct gct	2224
Thr Glu Ser Asn Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala	
465 470 475	
cca gtt gct gct gcc gcc act gct gcc gcc atc act gcc act gct gcc	2272
Pro Val Ala Ala Ala Ala Thr Ala Ala Ala Ile Thr Ala Thr Ala Ala	
480 485 490	
acc atc acc acc acc atg gta gct gct gct cca gtt gct gtt gct gct	2320
Thr Ile Thr Thr Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala	
495 500 505	
gct gct gct cca gct gct gct gct gcc ccg tct cca gcc act gcc gct	2368
Ala Ala Ala Pro Ala Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala	
510 515 520	
gct act gct gct gct gtt tct cca gct gct gct ggt cag att cca gct	2416
Ala Thr Ala Ala Ala Val Ser Pro Ala Ala Ala Gly Gln Ile Pro Ala	
525 530 535 540	
gct gcc tct gtt gcc tca gct gct gcc gtt gct cct tct gct gct gct	2464
Ala Ala Ser Val Ala Ser Ala Ala Val Ala Pro Ser Ala Ala Ala	
545 550 555	
gct gct gct gtt cag gtt gct cca gct gct ccg gct cca gtt cca gct	2512
Ala Ala Ala Val Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala	
560 565 570	
ccg gct ctg gtt ccg gtt cca gct cca gca gcg gct cag gct tct gct	2560
Pro Ala Leu Val Pro Val Pro Ala Pro Ala Ala Ala Gln Ala Ser Ala	
575 580 585	
cct gct cag act cag gca cca act tca gct ccg gct gtg gct cca act	2608
Pro Ala Gln Thr Gln Ala Pro Thr Ser Ala Pro Val Ala Pro Thr	
590 595 600	

```

cca gct cca act cca act cca gct gtg gct cag gct gag gtt cct gca 2656
Pro Ala Pro Thr Pro Thr Pro Ala Val Ala Gln Ala Glu Val Pro Ala
605                      610                      615                      620

agt cca gct acc ggt cct gga cca cat cgt ttg tct ata cca agt ttg 2704
Ser Pro Ala Thr Gly Pro Gly Pro His Arg Leu Ser Ile Pro Ser Leu
625                      630                      635

acc tgc aat cca gac aaa aca gat ggg cct gtg ttc cac tcc aat act 2752
Thr Cys Asn Pro Asp Lys Thr Asp Gly Pro Val Phe His Ser Asn Thr
640                      645                      650

ctg gaa aga aaa act ccc att cag atc ctg gga caa gag cct gat gca 2800
Leu Glu Arg Lys Thr Pro Ile Gln Ile Leu Gly Gln Glu Pro Asp Ala
655                      660                      665

gag atg gtg gaa tat ctc atc taa acggccaaat caagagctgc agattatcag 2854
Glu Met Val Glu Tyr Leu Ile
670                      675

caaaaatgct tttaatcatt ttcccccttt tattggttct tgttttgagg gtgaggacaa 2914

gggttggtggg gaggggatgt tttttaacag gactttttat tggaacaatg tactacttga 2974

gtaataccat gtgaacacca gtctattttg gtatgcttag ggagtacctc taaagacaga 3034

ttaatcagaa tgtgctctaa agcttattgt ttgaatttat acgaatactg ggactgttaa 3094

caggtggcta tacatcgacg ttttcaatgt gcttaaattt gtttaaattt tccatattct 3154

agatcatttt ttattgaaga gcacagtatg tgtggaagac agtgtataac acgtagtttg 3214

gaagtgggaa gctagagaga attgagtgtg tgctgttttg tatagttact atcctgtgca 3274

gcagctggag aaagcactca cctcaggctt acaaaagga atagtttcag gagctatgta 3334

agctggaaaa aaggtagggg gttttggggg gcagaagggt actggagcta attttttctt 3394

ccagtttccc agctaccctg cccaggggaa ttgtgtttgt cttcatttca gtgggtgcttt 3454

ggaaatggat tcttttggtt cctcctgga ggttcatata ttcatatata tgctctggag 3514

taatttatgc atttggataa ttaatatatt gctttcagat gctgggagag tacattaact 3574

gagtgatgog caacttctc tctcttaggg aattagacca tcagaggcct tgatggagag 3634

ttgcatgggg tgctatatgc agacttccat ggtttgtgtg tagccatgaa cacagcttgc 3694

ttgcatttag taagaccaat cagcttagtg tttatttctt ctacagcaca gattcaactgg 3754

ctgggtctcc agtctcaaat tgccaatcat ttgcaaagtg aggaaggatc tttgttgaca 3814

```

ggttgaatgc tttgaatttc tggtgactac tttgaaataa cttgttttgt ttgtcaaatt 3874  
ctaagcatat gtcttaaaag gcatttttga ctatcacctc caaggggaata gcttgagaaa 3934  
cccaaagtac tatgctgcag tcgggggaga ggtggattgc agcagtatcc tcaactacct 3994  
cttctcactg tcagtgcacac catcttggaa tacctttggg aagcagcagg aaatgtgcat 4054  
gtgggtagag atcaaaggag gcaatggctc caagccttgc catagggctg cctccaagga 4114  
cacagaagga tgccagttgc cacaggctcc tgccctgtgt cacctgtctg cccttcatta 4174  
aggtgagaaa tctgcagata gcatcattaa gatcagtttt aaggggtata gggaggggtga 4234  
gggaagtggg ggggtgttagg taagggttgg gggtagaggt tttgggatgt cttagttaga 4294  
aaccagatta atagaagagt aggcctgata tattacatca tgagccatag tgggtgggaaa 4354  
gaacttttagc aatatagccc tacctcctca ttttagtgat gaggaatctg agaactggag 4414  
aggttcagtg actttttgaa agtcatacaa cacagctaac cattatgcca atcaccatgc 4474  
ttattttggg aaactcttta tcttttttaa attccatttt atgaaaaggc atcttcatgg 4534  
tccagggaaat atgtatcttg taaaatgtac ctggttggag tagcttgtcc agtcttgaca 4594  
aactactgaa tttctgtctt gcctctcctt cagtgccttt taaaagggtt tcccttttct 4654  
gatctgcatt tcaacataga gtcacataaa tgtccctctg agaaaccaat cccacttctt 4714  
tctaggagat tgggtatctt agataatctt ttgggggttc tctgtgagta taggaatgg 4774  
atccttccta attatcttcc aaaggaatta ttttgtgtgt gtgcctgtgt gtgtgtagag 4834  
acataaagga gggatgatgtg attttcagct agtcctttca cattttcaat aatgaggtaa 4894  
tcatgttaca tacacattag tcctcagtta taaagtgaat ctcagataga aattaaaagt 4954  
gcagttgtgt taagactctt tcatactacc ctttagtcat aaggagaaaa aaacactcaa 5014  
atagtagaag cagcaagtag caaacttcag gagagctact ttctatccaa ataatttaaa 5074  
aaacactttt cacctactcc tttcatgggt ataacacatt ggcagacttt ttgctggctc 5134  
tgggagccat gattttaatc acattctgca aggtgacaaa tgtcatacat tccacattgt 5194  
gtggtagcca tctctttaga ctcatgtgtt ttggggaaag gaagaagttc ttggctgagt 5254  
actattttga actttccaga accctctcac accagagaca gttcttctct gttcagtttc 5314  
caatccccga taatttgcta aaataacatt gtacatccaa gagagggaag aagagtatgt 5374

cagtatatta tgcagaagat agatacagcc ttttcagaag atctccacta gtttttgttc 5434  
 caaaaattca agtttatggg agaaatctca attagccacc ttttcacagt tgtgtggata 5494  
 taacatttgg gggatcttctc tggactccta cctatctgtg catcttaccg gcacctcagg 5554  
 aaaggagggt gaccagggtg tcttagcttg tactgcttgg tgatctctga ggaccttcta 5614  
 attcagttgt accccagtgt tccatgtata gaaaaacttc attagaacaa actttacttg 5674  
 atatgaaact cctattaaca gtcttttttt gaaataaaaa gtagcttgag cttctcttta 5734  
 aaatcatgta tcttgattgt tgatttaatg aaggatttcc ttttaatgct gcttttgagc 5794  
 ttcaaggtaa taggacagca ggaacctaaa atatctgcc aatcttgcca taggaaagat 5854  
 acccagagac ccatcatgtt ctctttttgt tgttacactg ttgggtgggt ataacaattg 5914  
 gaaaatgaac aaactgattg attgtgcaaa ctacttttta tgacaagcct aaacctcat 5974  
 aatgcggcag cttaaagtgt atacatatgc actaactttg atcaattata ttctcatatc 6034  
 tgtagctac acagtctcct attatctcaa ttgcttatgt gcatatggaa tatgttactt 6094  
 aaaacgtgtg cattcttact gaaaatgttt tcaaaggaag gtatcagctg tgggctaatt 6154  
 gccaccaatt tcagcctgcc acgattcttg gaaatatgtc ttccaagtgc catccatcat 6214  
 cagtaggaca agtgtcggga gtttgtttat tttttccag tagcaacgat gggttacatg 6274  
 gagccatgaa acctccttct ggctcctt gtgattaatg gcatgtgttt gtaaaatgga 6334  
 tagctggggg tggcagatgg ctagagaaga atcgcttttg gtttaaatg tatgtggtcc 6394  
 cctaattgatt gtgaccccat tctgtaatca actgagctag ttccaataaa gttaagcagg 6454  
 tttaaatcc 6463

<210> 2

<211> 675

<212> PRT

<213> Homo sapiens

<400> 2

Met	Pro	Arg	Ala	Gln	Pro	Ser	Ser	Ala	Ser	Tyr	Gln	Pro	Val	Pro	Ala
1					5				10				15		

Asp	Pro	Phe	Ala	Ile	Val	Ser	Arg	Ala	Gln	Gln	Met	Val	Glu	Ile	Leu
			20					25					30		

Ser Asp Glu Asn Arg Asn Leu Arg Gln Glu Leu Glu Gly Cys Tyr Glu  
 35 40 45  
 Lys Val Ala Arg Leu Gln Lys Val Glu Thr Glu Ile Gln Arg Val Ser  
 50 55 60  
 Glu Ala Tyr Glu Asn Leu Val Lys Ser Ser Ser Lys Arg Glu Ala Leu  
 65 70 75 80  
 Glu Lys Ala Met Arg Asn Lys Leu Glu Gly Glu Ile Arg Arg Met His  
 85 90 95  
 Asp Phe Asn Arg Asp Leu Arg Glu Arg Leu Glu Thr Ala Asn Lys Gln  
 100 105 110  
 Leu Ala Glu Lys Glu Tyr Glu Gly Ser Glu Asp Thr Arg Lys Thr Ile  
 115 120 125  
 Ser Gln Leu Phe Ala Lys Asn Lys Glu Ser Gln Arg Glu Lys Glu Lys  
 130 135 140  
 Leu Glu Ala Glu Leu Ala Thr Ala Arg Ser Thr Asn Glu Asp Gln Arg  
 145 150 155 160  
 Arg His Ile Glu Ile Arg Asp Gln Ala Leu Ser Asn Ala Gln Ala Lys  
 165 170 175  
 Val Val Lys Leu Glu Glu Glu Leu Lys Lys Lys Gln Val Tyr Val Asp  
 180 185 190  
 Lys Val Glu Lys Met Gln Gln Ala Leu Val Gln Leu Gln Ala Ala Cys  
 195 200 205  
 Glu Lys Arg Glu Gln Leu Glu His Arg Leu Arg Thr Arg Leu Glu Arg  
 210 215 220  
 Glu Leu Glu Ser Leu Arg Ile Gln Gln Arg Gln Gly Asn Cys Gln Pro  
 225 230 235 240  
 Thr Asn Val Ser Glu Tyr Asn Ala Ala Ala Leu Met Glu Leu Leu Arg  
 245 250 255  
 Glu Lys Glu Glu Arg Ile Leu Ala Leu Glu Ala Asp Met Thr Lys Trp  
 260 265 270  
 Glu Gln Lys Tyr Leu Glu Glu Asn Val Met Arg His Phe Ala Leu Asp  
 275 280 285  
 Ala Ala Ala Thr Val Ala Ala Gln Arg Asp Thr Thr Val Ile Ser His  
 290 295 300

Ser Pro Asn Thr Ser Tyr Asp Thr Ala Leu Glu Ala Arg Ile Gln Lys  
 305 310 315 320  
 Glu Glu Glu Glu Ile Leu Met Ala Asn Lys Arg Cys Leu Asp Met Glu  
 325 330 335  
 Gly Arg Ile Lys Thr Leu His Ala Gln Ile Ile Glu Lys Asp Ala Met  
 340 345 350  
 Ile Lys Val Leu Gln Gln Arg Ser Arg Lys Glu Pro Ser Lys Thr Glu  
 355 360 365  
 Gln Leu Ser Cys Met Arg Pro Ala Lys Ser Leu Met Ser Ile Ser Asn  
 370 375 380  
 Ala Gly Ser Gly Leu Leu Ser His Ser Ser Thr Leu Thr Gly Ser Pro  
 385 390 395 400  
 Ile Met Glu Glu Lys Arg Asp Asp Lys Ser Trp Lys Gly Ser Leu Gly  
 405 410 415  
 Ile Leu Leu Gly Gly Asp Tyr Arg Ala Glu Tyr Val Pro Ser Thr Pro  
 420 425 430  
 Ser Pro Val Pro Pro Ser Thr Pro Leu Leu Ser Ala His Ser Lys Thr  
 435 440 445  
 Gly Ser Arg Asp Cys Ser Thr Gln Thr Glu Arg Gly Thr Glu Ser Asn  
 450 455 460  
 Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala Pro Val Ala Ala  
 465 470 475 480  
 Ala Ala Thr Ala Ala Ala Ile Thr Ala Thr Ala Ala Thr Ile Thr Thr  
 485 490 495  
 Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala Ala Ala Ala Pro  
 500 505 510  
 Ala Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala Ala Thr Ala Ala  
 515 520 525  
 Ala Val Ser Pro Ala Ala Ala Gly Gln Ile Pro Ala Ala Ala Ser Val  
 530 535 540  
 Ala Ser Ala Ala Ala Val Ala Pro Ser Ala Ala Ala Ala Ala Val  
 545 550 555 560  
 Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala Pro Ala Leu Val  
 565 570 575

Pro Val Pro Ala Pro Ala Ala Ala Gln Ala Ser Ala Pro Ala Gln Thr  
                   580                                  585                                  590

Gln Ala Pro Thr Ser Ala Pro Ala Val Ala Pro Thr Pro Ala Pro Thr  
                   595                                  600                                  605

Pro Thr Pro Ala Val Ala Gln Ala Glu Val Pro Ala Ser Pro Ala Thr  
                   610                                  615                                  620

Gly Pro Gly Pro His Arg Leu Ser Ile Pro Ser Leu Thr Cys Asn Pro  
                   625                                  630                                  635                                  640

Asp Lys Thr Asp Gly Pro Val Phe His Ser Asn Thr Leu Glu Arg Lys  
                                   645                                  650                                  655

Thr Pro Ile Gln Ile Leu Gly Gln Glu Pro Asp Ala Glu Met Val Glu  
                                   660                                  665                                  670

Tyr Leu Ile  
                   675

<210> 3  
 <211> 675  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> ()...  
 <223> Residue 135 = Asn, Ser or Asp

<220>  
 <221> VARIANT  
 <222> ()...(150)  
 <223> Residues 148-150 = Glu-Leu-Ala or Thr-Thr-Pro

<400> 3  
 Met Pro Arg Ala Gln Pro Ser Ser Ala Ser Tyr Gln Pro Val Pro Ala  
   1                                  5                                  10                                  15

Asp Pro Phe Ala Ile Val Ser Arg Ala Gln Gln Met Val Glu Ile Leu  
                   20                                  25                                  30

Ser Asp Glu Asn Arg Asn Leu Arg Gln Glu Leu Glu Gly Cys Tyr Glu  
                   35                                  40                                  45

Lys Val Ala Arg Leu Gln Lys Val Glu Thr Glu Ile Gln Arg Val Ser  
                   50                                  55                                  60

Glu Ala Tyr Glu Asn Leu Val Lys Ser Ser Ser Lys Arg Glu Ala Leu  
                   65                                  70                                  75                                  80

Glu Lys Ala Met Arg Asn Lys Leu Glu Gly Glu Ile Arg Arg Met His  
                                   85                                  90                                  95

Asp Phe Asn Arg Asp Leu Arg Glu Arg Leu Glu Thr Ala Asn Lys Gln  
                                   100                                  105                                  110

Leu Ala Glu Lys Glu Tyr Glu Gly Ser Glu Asp Thr Arg Lys Thr Ile  
                                   115                                  120                                  125

Ser Gln Leu Phe Ala Lys Xaa Lys Glu Ser Gln Arg Glu Lys Glu Lys  
                                   130                                  135                                  140

Leu Glu Ala Xaa Xaa Xaa Thr Ala Arg Ser Thr Asn Glu Asp Gln Arg  
 145                                  150                                  155                                  160

Arg His Ile Glu Ile Arg Asp Gln Ala Leu Ser Asn Ala Gln Ala Lys  
                                   165                                  170                                  175

Val Val Lys Leu Glu Glu Glu Leu Lys Lys Lys Gln Val Tyr Val Asp  
                                   180                                  185                                  190

Lys Val Glu Lys Met Gln Gln Ala Leu Val Gln Leu Gln Ala Ala Cys  
                                   195                                  200                                  205

Glu Lys Arg Glu Gln Leu Glu His Arg Leu Arg Thr Arg Leu Glu Arg  
                                   210                                  215                                  220

Glu Leu Glu Ser Leu Arg Ile Gln Gln Arg Gln Gly Asn Cys Gln Pro  
 225                                  230                                  235                                  240

Thr Asn Val Ser Glu Tyr Asn Ala Ala Ala Leu Met Glu Leu Leu Arg  
                                   245                                  250                                  255

Glu Lys Glu Glu Arg Ile Leu Ala Leu Glu Ala Asp Met Thr Lys Trp  
                                   260                                  265                                  270

Glu Gln Lys Tyr Leu Glu Glu Asn Val Met Arg His Phe Ala Leu Asp  
                                   275                                  280                                  285

Ala Ala Ala Thr Val Ala Ala Gln Arg Asp Thr Thr Val Ile Ser His  
                                   290                                  295                                  300

Ser Pro Asn Thr Ser Tyr Asp Thr Ala Leu Glu Ala Arg Ile Gln Lys  
 305                                  310                                  315                                  320

Glu Glu Glu Glu Ile Leu Met Ala Asn Lys Arg Cys Leu Asp Met Glu  
                                   325                                  330                                  335

Gly Arg Ile Lys Thr Leu His Ala Gln Ile Ile Glu Lys Asp Ala Met  
                                   340                                  345                                  350



Ile Lys Val Leu Gln Gln Arg Ser Arg Lys Glu Pro Ser Lys Thr Glu  
 355 360 365  
 Gln Leu Ser Cys Met Arg Pro Ala Lys Ser Leu Met Ser Ile Ser Asn  
 370 375 380  
 Ala Gly Ser Gly Leu Leu Ser His Ser Ser Thr Leu Thr Gly Ser Pro  
 385 390 395 400  
 Ile Met Glu Glu Lys Arg Asp Asp Lys Ser Trp Lys Gly Ser Leu Gly  
 405 410 415  
 Ile Leu Leu Gly Gly Asp Tyr Arg Ala Glu Tyr Val Pro Ser Thr Pro  
 420 425 430  
 Ser Pro Val Pro Pro Ser Thr Pro Leu Leu Ser Ala His Ser Lys Thr  
 435 440 445  
 Gly Ser Arg Asp Cys Ser Thr Gln Thr Glu Arg Gly Thr Glu Ser Asn  
 450 455 460  
 Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala Pro Val Ala Ala  
 465 470 475 480  
 Ala Ala Thr Ala Ala Ala Ile Thr Ala Thr Ala Ala Thr Ile Thr Thr  
 485 490 495  
 Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala Ala Ala Pro  
 500 505 510  
 Ala Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala Ala Thr Ala Ala  
 515 520 525  
 Ala Val Ser Pro Ala Ala Ala Gly Gln Ile Pro Ala Ala Ala Ser Val  
 530 535 540  
 Ala Ser Ala Ala Ala Val Ala Pro Ser Ala Ala Ala Ala Ala Val  
 545 550 555 560  
 Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala Pro Ala Leu Val  
 565 570 575  
 Pro Val Pro Ala Pro Ala Ala Ala Gln Ala Ser Ala Pro Ala Gln Thr  
 580 585 590  
 Gln Ala Pro Thr Ser Ala Pro Ala Val Ala Pro Thr Pro Ala Pro Thr  
 595 600 605  
 Pro Thr Pro Ala Val Ala Gln Ala Glu Val Pro Ala Ser Pro Ala Thr  
 610 615 620

Gly Pro Gly Pro His Arg Leu Ser Ile Pro Ser Leu Thr Cys Asn Pro  
625 630 635 640

Asp Lys Thr Asp Gly Pro Val Phe His Ser Asn Thr Leu Glu Arg Lys  
645 650 655

Thr Pro Ile Gln Ile Leu Gly Gln Glu Pro Asp Ala Glu Met Val Glu  
660 665 670

Tyr Leu Ile  
675

<210> 4

<211> 143

<212> PRT

<213> Homo sapiens

<400> 4

Glu Ser Asn Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala Pro  
1 5 10 15

Val Ala Ala Ala Ala Thr Ala Ala Ala Ile Thr Ala Thr Ala Ala Thr  
20 25 30

Ile Thr Thr Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala Ala  
35 40 45

Ala Ala Pro Ala Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala Ala  
50 55 60

Thr Ala Ala Ala Val Ser Pro Ala Ala Ala Gly Gln Ile Pro Ala Ala  
65 70 75 80

Ala Ser Val Ala Ser Ala Ala Ala Val Ala Pro Ser Ala Ala Ala Ala  
85 90 95

Ala Ala Val Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala Pro  
100 105 110

Ala Leu Val Pro Val Pro Ala Pro Ala Ala Ala Gln Ala Ser Ala Pro  
115 120 125

Ala Gln Thr Gln Ala Pro Thr Ser Ala Pro Ala Val Ala Pro Thr  
130 135 140

<210> 5

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for PCR reaction

<400> 5

tacggatccg aatcgaacaa aactgcagct g

31

<210> 6

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for PCR reaction

<400> 6

atactcgagt catggagctg gagttggagc ca

32

<210> 7

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for PCR reaction

<400> 7

gtttgacctg caatccagac aa

22

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for PCR reaction

<400> 8

cccaggatct gaatgggagt t

21

<210> 9

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for PCR reaction

<400> 9

cagatggggcc tgtgttcac tccaa

25

<210> 10

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for RACE PCR reaction

<400> 10

gctgacagtt gccctgacgc tgct

24

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for RACE PCR reaction

<400> 11

cggagacggt gctctagctg ctca

24

<210> 12

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for RACE PCR reaction

<400> 12

tccttccaac tcttgctca agttccg

27

<210> 13

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for RACE PCR reaction

<400> 13

ggtggcagcg gacaggcagg atac

24

<210> 14

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for RACE PCR reaction

<400> 14

gaggcggaga gaactaagag aaga

24

<210> 15

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide  
primer for RACE PCR reaction

<400> 15

gagcggagat ggaggagtaa ttca

24

## INTERNATIONAL SEARCH REPORT

International Application No

PC./EP 99/04109

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N5/10 C12N1/21 C07K14/71 C07K16/28  
G01N33/50 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 206 400 A (TNO) 30 December 1986 (1986-12-30) claims 2,8	1,2, 26-30
X	KOST C ET AL: "Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor" EUR J BIOCHEM, vol. 236, no. 2, 1 March 1996 (1996-03-01), pages 682-688, XP002121364 figure 3	1,2

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 "&" document member of the same patent family

Date of the actual completion of the international search

3 November 1999

Date of mailing of the international search report

17/11/1999

Name and mailing address of the ISA

European Patent Office, P. B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lonnø, 0

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMSTS E.M.B.L. Databases Accession Number: G16015, 25 January 1996 (1996-01-25) MURRAY M ET AL: "Human STS CHLC.GCT14C05.P16699" XP002121366 92.9% identity in 280bp overlap with SeqIdNo.1 abstract</p>	17
A	<p>CLAESSON-WELSH L ET AL: "Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 95, no. 10, 12 May 1998 (1998-05-12), pages 5579-5583, XP002121365 abstract</p>	1-30
P,A	<p>MOSER T EL AL: "Angiostatin binds ATP synthase on the surface of human endothelial cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 96, no. 6, 16 March 1999 (1999-03-16), pages 2811-2816, XP002121371</p>	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/04109

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
See FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 99 04109

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

A compound or group of compounds is not sufficiently defined only by its pharmacological parameters or properties: for a fully valid definition of a compound or a group of compounds, a structural definition is needed. A complete search of the subject-matter of claims 27-30 is virtually impossible because it is not exhaustively known which chemical compounds are comprised by the scope of these claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/04109

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0206400 A	30-12-1986	NL 8501682 A	02-01-1987
		AT 48142 T	15-12-1989
		JP 1956575 C	10-08-1995
		JP 6076438 B	28-09-1994
		JP 62181299 A	08-08-1987
		US 5064942 A	12-11-1991
		US 4853220 A	01-08-1989
<hr/>			